New York State Common Retirement Fund Raises Stock Position in Icon Plc (NASDAQ:ICLR)

New York State Common Retirement Fund boosted its holdings in Icon Plc (NASDAQ:ICLR) by 1.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 334,779 shares of the medical research company’s stock after buying an additional 3,800 shares during the period. New York State Common Retirement Fund owned 0.62% of Icon worth $57,659,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Amundi Pioneer Asset Management Inc. lifted its position in shares of Icon by 2.1% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 24,400 shares of the medical research company’s stock worth $3,332,000 after buying an additional 500 shares during the last quarter. Vanguard Group Inc. increased its holdings in Icon by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 19,638 shares of the medical research company’s stock worth $3,024,000 after purchasing an additional 493 shares in the last quarter. UBS Asset Management Americas Inc. increased its holdings in Icon by 30.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock worth $50,000 after purchasing an additional 77 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in Icon by 10.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 126,318 shares of the medical research company’s stock worth $18,612,000 after purchasing an additional 11,721 shares in the last quarter. Finally, Summit Creek Advisors LLC increased its holdings in Icon by 4.1% in the 3rd quarter. Summit Creek Advisors LLC now owns 147,879 shares of the medical research company’s stock worth $21,788,000 after purchasing an additional 5,890 shares in the last quarter. Institutional investors and hedge funds own 85.41% of the company’s stock.

A number of brokerages have issued reports on ICLR. Zacks Investment Research cut Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Citigroup began coverage on Icon in a report on Monday, January 6th. They issued a “neutral” rating and a $185.00 target price for the company. SunTrust Banks cut Icon from a “buy” rating to a “hold” rating and upped their target price for the stock from $170.00 to $182.00 in a report on Monday, January 27th. BidaskClub raised Icon from a “hold” rating to a “buy” rating in a report on Friday, January 17th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $160.00 target price on shares of Icon in a report on Monday, October 28th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Icon has a consensus rating of “Hold” and a consensus target price of $171.89.

Shares of ICLR stock opened at $174.92 on Thursday. The stock has a market cap of $9.26 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 2.07 and a beta of 0.77. The stock has a 50-day moving average of $171.39 and a 200-day moving average of $158.18. The company has a current ratio of 2.03, a quick ratio of 2.03 and a debt-to-equity ratio of 0.28. Icon Plc has a 1-year low of $127.58 and a 1-year high of $176.98.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Story: What is a capital gain?

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.